InvestorsHub Logo
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

Re: None

Tuesday, 01/22/2019 11:11:23 AM

Tuesday, January 22, 2019 11:11:23 AM

Post# of 443
News: $AMGN European Commission Approves BLINCYTO® (blinatumomab) In Patients With Philadelphia Chromosome Negative Minimal Residual Disease-Positive B-cell Precursor Acute Lymphoblastic Leukemia

THOUSAND OAKS, Calif. , Jan. 22, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved an expanded indication for BLINCYTO ® (blinatumomab) monotherapy to include adult patients with Philadelphia chromosome negative (Ph-) CD19 po...

Read the whole news https://marketwirenews.com/news-releases/european-commission-approves-blincyto-xae-blinatumomab-in-patients-with-philadelphia-chromosome-negative-minimal-residual-disease-positive-b-cell-precursor-acute-lymphoblastic-leukemia-7420084.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMGN News